close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

7.800 -0.040 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 267,808
Open 7.960
Bid (Size) 7.810 (100)
Ask (Size) 7.830 (100)
Prev. Close 7.840
Today's Range 7.770 - 8.080
52wk Range 1.780 - 8.447
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+99.0%
+99.0%
1 Month
+22.6%
+22.6%
3 Month
+114.9%
+114.9%
6 Month
+165.3%
+165.3%
1 Year
+57.6%
+57.6%

More News

Read More
News headline image
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
Via Benzinga
News headline image
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026 ↗
Via Benzinga
News headline image
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? ↗
Via Benzinga
News headline image
This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
Via Benzinga
News headline image
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
News headline image
ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)
From Grabar Law Office
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is
From Grabar Law Office
Via GlobeNewswire

Frequently Asked Questions

Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?
Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?
The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market
What is the current price of Kyverna Therapeutics, Inc. - Common Stock?
The current price of Kyverna Therapeutics, Inc. - Common Stock is 7.800
When was Kyverna Therapeutics, Inc. - Common Stock last traded?
The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 12/05/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today